Likelihood of Approval and Phase Transition Success Rate Model – Itacitinib Adipate in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Itacitinib Adipate in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Itacitinib Adipate in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details:
Itacitinib adipate (INCB-39110) is under development for the treatment of cytokine release syndrome, advanced solid tumor malignancies including sporadic hemophagocytosis lymphohistiocytosis (HLHs), advanced hepatocellular carcinoma, T-Cell Leukemia, transitional cell carcinoma, primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF), post essential thrombocythemia myelofibrosis (PET-MF), B-cell lymphomas including indolent, aggressive B-cell non- Hodgkin’s lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, diffuse large B-cell lymphoma, Hodgkin’s lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, relapsed and refractory overlap syndromes, metastatic non-small cell lung cancer, acute myeloid leukemia(AML), acute lymphocytic leukemia (ALL). The drug candidate is administered orally as a tablet. INCB-39110 targets Janus kinase 1 (JAK1). The drug candidate was also under development for soft tissue sarcoma such as leiomyosarcoma, synovial sarcoma, pleomorphic undifferentiated sarcoma, myxoid or round cell liposarcoma, pancreatic ductal adenocarcinoma, moderate to severe ulcerative colitis, renal cell carcinoma, rheumatoid arthritis, chronic plaque psoriasis, endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, triple negative breast cancer, small cell lung cancer, urothelial cancer, ureter cancer, bladder, urethral cancer, post-lung transplant bronchiolitis obliterans syndrome (BOS) and acute graft versus host disease.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Itacitinib Adipate LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports